OSIRIS THERAPEUTICS, INC.

Delayed Nasdaq  - 
0.000000 USD    0.00%
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hagens Berman: Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to File Claims to Receive Part of $18.5 Million Settlement

01/24/2019 | 05:39pm EDT

National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached an $18.5 million settlement on behalf of investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) (“Osiris” or the “Company”) who purchased shares between May 12, 2014 and November 16, 2015. The class action alleged violations of the federal securities laws. Named as defendants were Osiris, Lode Debrabandere, Gregory Law and Philip R. Jacoby, Jr. Settlement is pending final approval.

Class Members have until January 30, 2019 to submit a Proof of Claim and Release to receive a payment from the class action settlement.

If you purchased or otherwise acquired Osiris shares between May 12, 2014, and November 16, 2015, you may submit a claim for the settlement by visiting the following link to download the claim form.

You may mail your completed and signed Proof of Claim and Release, postmarked no later than January 30, 2019, to the Settlement Administrator at:

Osiris Securities Settlement
Settlement Administrator
P.O. Box 4129
Portland, OR 97208-4129
info@OsirisSecuritiesSettlement.com

About Hagens Berman

Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 80+ attorneys in 10 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.


ę Business Wire 2019
All news about OSIRIS THERAPEUTICS, INC.
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Ther..
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OS..
PR
2019ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
PR
2019OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout
BU
2019Smith & Nephew to buy Osiris in regenerative products push
RE
2019OSIRIS THERAPEUTICS : Smith & Nephew expands in high growth regenerative medicine market t..
PR
2019Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
GL
2019HAGENS BERMAN : Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to ..
BU
More news
Managers and Directors
Samson Tom President & Chief Executive Officer
Laine Dyess Vice President-Sales
Heather Hill VP-Regulatory Affairs & Quality Assurance
Jeffrey Levin Vice President-Human Resources
Sector and Competitors
1st jan.Capi. (M$)
OSIRIS THERAPEUTICS, INC.40.67%0
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-16.20%42 682
BIONTECH SE-38.01%38 834